Brief: Amicus Therapeutics Q3 Revenue USD 141.5 Million Vs. IBES Estimate USD 135.3 Million
Nov 06 (Reuters) - Amicus Therapeutics Q3 net income USD -6.7 million. * Q3 EPS USD -0.02 * Q3 adjusted operating expenses USD 82.6 million * Q3 operating expenses USD 106.6 million
Recent news on Amicus Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Amicus Q4 revenue beats estimates